Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Bibliographic Details
Main Authors: A Boland, A Bagust, J Hockenhull, H Davis, P Chu, R Dickson
Format: Article
Language:English
Published: NIHR Journals Library 2009-09-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta13suppl2/06
id doaj-69d5b328de214f19ae6929e2d5d1fa0c
record_format Article
spelling doaj-69d5b328de214f19ae6929e2d5d1fa0c2020-11-24T23:40:14ZengNIHR Journals LibraryHealth Technology Assessment1366-52782009-09-0113 Suppl 210.3310/hta13suppl2/06Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphomaA Boland0A BagustJ HockenhullH DavisP ChuR DicksonLiverpool Reviews and Implementation Group, Sherrington Buildings, University of Liverpool, Liverpool, UKhttps://doi.org/10.3310/hta13suppl2/06
collection DOAJ
language English
format Article
sources DOAJ
author A Boland
A Bagust
J Hockenhull
H Davis
P Chu
R Dickson
spellingShingle A Boland
A Bagust
J Hockenhull
H Davis
P Chu
R Dickson
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
Health Technology Assessment
author_facet A Boland
A Bagust
J Hockenhull
H Davis
P Chu
R Dickson
author_sort A Boland
title Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
title_short Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
title_full Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
title_fullStr Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
title_full_unstemmed Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
title_sort rituximab for the treatment of relapsed or refractory stage iii or iv follicular non-hodgkin's lymphoma
publisher NIHR Journals Library
series Health Technology Assessment
issn 1366-5278
publishDate 2009-09-01
url https://doi.org/10.3310/hta13suppl2/06
work_keys_str_mv AT aboland rituximabforthetreatmentofrelapsedorrefractorystageiiiorivfollicularnonhodgkinslymphoma
AT abagust rituximabforthetreatmentofrelapsedorrefractorystageiiiorivfollicularnonhodgkinslymphoma
AT jhockenhull rituximabforthetreatmentofrelapsedorrefractorystageiiiorivfollicularnonhodgkinslymphoma
AT hdavis rituximabforthetreatmentofrelapsedorrefractorystageiiiorivfollicularnonhodgkinslymphoma
AT pchu rituximabforthetreatmentofrelapsedorrefractorystageiiiorivfollicularnonhodgkinslymphoma
AT rdickson rituximabforthetreatmentofrelapsedorrefractorystageiiiorivfollicularnonhodgkinslymphoma
_version_ 1725510531278700544

Similar Items